Connecting oncology professionals with relevant clinical trials

Selected clinical trial

PATAGONIA: A Global, Multicentre, Phase II Platform Study of Datopotamab Deruxtecan-based Combinations in TROP2 NMR-positive Non-small Cell Lung Cancer

Sponsor: AstraZeneca AB

Phase: 2

Disease: Non-small cell lung cancer, Non-squamous NSCLC

EU trial number: 2025-524836-21-00

Population: Adults ≥18 years (or local age of majority) with unresectable stage IIIB/IIIC or metastatic stage IV non-squamous NSCLC prospectively TROP2 normalized membrane ratio-positive, without actionable genomic alterations including EGFR sensitizing mutations or ALK/ROS1 rearrangements and without prior first-line systemic treatment for advanced disease.

Register Investigator Interest

Interested in offering this trial to suitable patients?